Santhera Pharmaceuticals Holding AG – SIX:SANN.SW
Santhera Pharmaceuticals Holding AG stock price today
Santhera Pharmaceuticals Holding AG stock price monthly change
Santhera Pharmaceuticals Holding AG stock price quarterly change
Santhera Pharmaceuticals Holding AG stock price yearly change
Santhera Pharmaceuticals Holding AG key metrics
Market Cap | 138.00M |
Enterprise value | 32.15M |
P/E | -0.55 |
EV/Sales | 1.16 |
EV/EBITDA | -0.65 |
Price/Sales | 0.15 |
Price/Book | -0.30 |
PEG ratio | -0.03 |
EPS | 7.36 |
Revenue | 155.06M |
EBITDA | 80.62M |
Income | 82.17M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -200.82% |
Oper. margin | -195.61% |
Gross margin | 84.08% |
EBIT margin | -195.61% |
EBITDA margin | 51.99% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSanthera Pharmaceuticals Holding AG stock price history
Santhera Pharmaceuticals Holding AG stock forecast
Santhera Pharmaceuticals Holding AG financial statements
| Mar 2023 | 1.96M | -11.66M | -592.43% |
|---|---|---|---|
| Jun 2023 | 3.93M | -23.33M | -592.43% |
| Sep 2023 | 49.71M | 39.05M | 78.56% |
| Dec 2023 | 99.43M | 78.11M | 78.56% |
| 2025 | 60M | -10M | -16.67% |
|---|---|---|---|
| 2026 | 135M | 53M | 39.26% |
| 2027 | 130M | 55.35M | 42.58% |
| 2028 | 158M | 92.85M | 58.77% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 63075000 | 105.83M | 167.8% |
|---|---|---|---|
| Jun 2023 | 63075000 | 105.83M | 167.8% |
| Sep 2023 | 109629000 | 49.16M | 44.85% |
| Dec 2023 | 109629000 | 49.68M | 45.32% |
| Mar 2023 | -7.67M | 2.84M | 4.98M |
|---|---|---|---|
| Jun 2023 | -15.35M | 5.68M | 9.97M |
| Sep 2023 | 31.49M | -11.86M | -5.05M |
| Dec 2023 | 62.62M | -23.72M | -10.15M |
Santhera Pharmaceuticals Holding AG alternative data
| Aug 2023 | 45 |
|---|---|
| Sep 2023 | 45 |
| Oct 2023 | 45 |
| Nov 2023 | 45 |
| Dec 2023 | 45 |
| Jan 2024 | 45 |
| Feb 2024 | 45 |
| Mar 2024 | 45 |
| Apr 2024 | 45 |
| May 2024 | 45 |
| Jun 2024 | 45 |
| Jul 2024 | 44 |
Santhera Pharmaceuticals Holding AG other data
| Insider | Compensation |
|---|---|
Mr. Dario Eklund (1968) Chief Executive Officer | $681,050 |
| Mr. Andrew P. Smith (1963) Chief Financial Officer | $446,440 |
| Dr. Thomas Meier Ph.D. (1962) Founder & Director | $90,490 |
-
What's the price of Santhera Pharmaceuticals Holding AG stock today?
One share of Santhera Pharmaceuticals Holding AG stock can currently be purchased for approximately $1.3.
-
When is Santhera Pharmaceuticals Holding AG's next earnings date?
Unfortunately, Santhera Pharmaceuticals Holding AG's (SANN.SW) next earnings date is currently unknown.
-
Does Santhera Pharmaceuticals Holding AG pay dividends?
No, Santhera Pharmaceuticals Holding AG does not pay dividends.
-
How much money does Santhera Pharmaceuticals Holding AG make?
Santhera Pharmaceuticals Holding AG has a market capitalization of 138.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1283.84% to 103.41M US dollars.
-
What is Santhera Pharmaceuticals Holding AG's stock symbol?
Santhera Pharmaceuticals Holding AG is traded on the SIX under the ticker symbol "SANN.SW".
-
What is Santhera Pharmaceuticals Holding AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Santhera Pharmaceuticals Holding AG?
Shares of Santhera Pharmaceuticals Holding AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Santhera Pharmaceuticals Holding AG's key executives?
Santhera Pharmaceuticals Holding AG's management team includes the following people:
- Mr. Dario Eklund Chief Executive Officer(age: 57, pay: $681,050)
- Mr. Andrew P. Smith Chief Financial Officer(age: 62, pay: $446,440)
- Dr. Thomas Meier Ph.D. Founder & Director(age: 63, pay: $90,490)
-
Is Santhera Pharmaceuticals Holding AG founder-led company?
Yes, Santhera Pharmaceuticals Holding AG is a company led by its founder Dr. Thomas Meier Ph.D..
-
How many employees does Santhera Pharmaceuticals Holding AG have?
As Jul 2024, Santhera Pharmaceuticals Holding AG employs 44 workers, which is 2% less then previous month and 2% less then previous quarter.
-
When Santhera Pharmaceuticals Holding AG went public?
Santhera Pharmaceuticals Holding AG is publicly traded company for more then 18 years since IPO on 3 Nov 2006.
-
What is Santhera Pharmaceuticals Holding AG's official website?
The official website for Santhera Pharmaceuticals Holding AG is santhera.com.
-
How can i contact Santhera Pharmaceuticals Holding AG?
Santhera Pharmaceuticals Holding AG can be reached via phone at +41 61 906 89 50.
Santhera Pharmaceuticals Holding AG company profile:
Santhera Pharmaceuticals Holding AG
santhera.comSIX
44
Biotechnology
Healthcare
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Pratteln, 4133
:
ISIN: CH1276028821
:
